219 research outputs found
Legal research methodologies in European Union and international law: research notes (part 2)
This is the second part of a series of three 'research note' articles looking at an AHRC funded project on the various research methodologies used by European Union and International Law researchers. The first part was published in the JCER (Volume 3: Issue 2 - 2007) third part will be published in September 2008
Uncertainty in humanities network visualization
Network visualization is one of the most widely used tools in digital humanities research. The idea of uncertain or “fuzzy” data is also a core notion in digital humanities research. Yet network visualizations in digital humanities do not always prominently represent uncertainty. In this article, we present a mathematical and logical model of uncertainty as a range of values which can be used in network visualizations. We review some of the principles for visualizing uncertainty of different kinds, visual variables that can be used for representing uncertainty, and how these variables have been used to represent different data types in visualizations drawn from a range of non-humanities fields like climate science and bioinformatics. We then provide examples of two diagrams: one in which the variables displaying degrees of uncertainty are integrated/pinto the graph and one in which glyphs are added to represent data certainty and uncertainty. Finally, we discuss how probabilistic data and what-if scenarios could be used to expand the representation of uncertainty in humanities network visualizations
Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members
[Background] Tic disorders belong to the broad spectrum of pediatric and adult movement disorders. The wide variability in clinical presentations, applied assessment tools, and treatments are poorly understood.[Objectives] To map practices and knowledge base of movement disorder clinicians concerning clinical features, pathophysiology, and treatment approaches in tic disorders.
[Methods] A 33-item survey was developed by the Tic Disorders and Tourette syndrome Study Group members of the Movement Disorder Society. The survey was distributed to the complete society membership and included responses from 346 members, 314 of whom reported treating tic disorders.
[Results] Approximately one third of survey respondents (35%) frequently evaluated patients with tics. The data revealed widespread use of existing guidelines (about 70%) and screening for comorbid disorders (>90%). The most common investigations used to rule out secondary causes of tics were imaging (92%), laboratory tests (66%) and neurophysiology (38%). Functional tics were the second most common tic etiology following primary tics. Only 27% of respondents reported confidence in knowledge about tic pathogenesis. Top rated interventions to treat tics were psychoeducation, cognitive behavioral intervention for tics (CBIT) and treatment for neuropsychiatric comorbidities. Antipsychotics were ranked as the most effective pharmacologic tic intervention.
Conclusions: The majority of movement disorders specialists do not frequently encounter tics. There was sparse knowledge about tic pathophysiology. Psychoeducation, CBIT, the treatment of neuropsychiatric comorbidities and use of antipsychotics emerged as the most common interventions to treat tics. These results provide insight into what will be needed to improve the diagnosis and treatment of tic disorders.CG is supported by the Freigeist Fellowship of the VolkswagenStiftung. He has served as ad hoc advisory board to Biomarin and received honoraria from the International Parkinsons Disease and Movement Disorders Society for educational activities
Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction
Despite the high prevalence of heart failure in the western world, there are few effective treatments. Fibulin-3 is a protein involved in extracellular matrix (ECM) structural integrity, however its role in the heart is unknown. We have demonstrated, using single cell RNA-seq, that fibulin-3 was highly expressed in quiescent murine cardiac fibroblasts, with expression highest prior to injury and late post-infarct (from ~ day-28 to week-8). In humans, fibulin-3 was upregulated in left ventricular tissue and plasma of heart failure patients. Fibulin-3 knockout (Efemp1−/−) and wildtype mice were subjected to experimental myocardial infarction. Fibulin-3 deletion resulted in significantly higher rate of cardiac rupture days 3–6 post-infarct, indicating a weak and poorly formed scar, with severe ventricular remodelling in surviving mice at day-28 post-infarct. Fibulin-3 knockout mice demonstrated less collagen deposition at day-3 post-infarct, with abnormal collagen fibre-alignment. RNA-seq on day-3 infarct tissue revealed upregulation of ECM degradation and inflammatory genes, but downregulation of ECM assembly/structure/organisation genes in fibulin-3 knockout mice. GSEA pathway analysis showed enrichment of inflammatory pathways and a depletion of ECM organisation pathways. Fibulin-3 originates from cardiac fibroblasts, is upregulated in human heart failure, and is necessary for correct ECM organisation/structural integrity of fibrotic tissue to prevent cardiac rupture post-infarct
Natural-abundance radiocarbon as a tracer of assimilation of petroleum carbon by bacteria in salt marsh sediments
Author Posting. © The Authors, 2005. This is the author's version of the work. It is posted here by permission of Elsevier B.V. for personal use, not for redistribution. The definitive version was published in Geochimica et Cosmochimica Acta 70 (2006): 1761-1771, doi:10.1016/j.gca.2005.12.020.The natural abundance of radiocarbon (14C) provides unique insight into the
source and cycling of sedimentary organic matter. Radiocarbon analysis of bacterial
phospholipid lipid fatty acids (PLFAs) in salt-marsh sediments of southeast Georgia
(USA) – one heavily contaminated by petroleum residues – was used to assess the fate of
petroleum-derived carbon in sediments and incorporation of fossil carbon into microbial
biomass. PLFAs that are common components of eubacterial cell membranes (e.g.,
branched C15 and C17, 10-methyl-C16) were depleted in 14C in the contaminated sediment
(mean Δ14C value of +25 ± 19 ‰ for bacterial PLFAs) relative to PLFAs in
uncontaminated “control” sediment (Δ14C = +101 ± 12‰). We suggest that the 14C-depletion
in bacterial PLFAs at the contaminated site results from microbial metabolism
of petroleum and subsequent incorporation of petroleum-derived carbon into bacterial
membrane lipids. A mass balance calculation indicates that 6-10% of the carbon in
bacterial PLFAs at the oiled site could derive from petroleum residues. These results
demonstrate that even weathered petroleum may contain components of sufficient lability
to be a carbon source for biomass production by marsh sediment microorganisms.
Furthermore, a small but significant fraction of fossil carbon is assimilated even in the
presence of a much larger pool of presumably more-labile and faster-cycling carbon
substrates.This study was supported by Georgia Sea Grant
(RR100-221/926784), the National Science Foundation (OCE-9911678) and NOSAMS
(thanks to J. M. Hayes)
Association Between Interstitial Lung Abnormalities and All-Cause Mortality.
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files.
This article is open access.Interstitial lung abnormalities have been associated with lower 6-minute walk distance, diffusion capacity for carbon monoxide, and total lung capacity. However, to our knowledge, an association with mortality has not been previously investigated.To investigate whether interstitial lung abnormalities are associated with increased mortality.Prospective cohort studies of 2633 participants from the FHS (Framingham Heart Study; computed tomographic [CT] scans obtained September 2008-March 2011), 5320 from the AGES-Reykjavik Study (Age Gene/Environment Susceptibility; recruited January 2002-February 2006), 2068 from the COPDGene Study (Chronic Obstructive Pulmonary Disease; recruited November 2007-April 2010), and 1670 from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; between December 2005-December 2006).Interstitial lung abnormality status as determined by chest CT evaluation.All-cause mortality over an approximate 3- to 9-year median follow-up time. Cause-of-death information was also examined in the AGES-Reykjavik cohort.Interstitial lung abnormalities were present in 177 (7%) of the 2633 participants from FHS, 378 (7%) of 5320 from AGES-Reykjavik, 156 (8%) of 2068 from COPDGene, and in 157 (9%) of 1670 from ECLIPSE. Over median follow-up times of approximately 3 to 9 years, there were more deaths (and a greater absolute rate of mortality) among participants with interstitial lung abnormalities when compared with those who did not have interstitial lung abnormalities in the following cohorts: 7% vs 1% in FHS (6% difference [95% CI, 2% to 10%]), 56% vs 33% in AGES-Reykjavik (23% difference [95% CI, 18% to 28%]), and 11% vs 5% in ECLIPSE (6% difference [95% CI, 1% to 11%]). After adjustment for covariates, interstitial lung abnormalities were associated with a higher risk of death in the FHS (hazard ratio [HR], 2.7 [95% CI, 1.1 to 6.5]; P = .03), AGES-Reykjavik (HR, 1.3 [95% CI, 1.2 to 1.4]; P < .001), COPDGene (HR, 1.8 [95% CI, 1.1 to 2.8]; P = .01), and ECLIPSE (HR, 1.4 [95% CI, 1.1 to 2.0]; P = .02) cohorts. In the AGES-Reykjavik cohort, the higher rate of mortality could be explained by a higher rate of death due to respiratory disease, specifically pulmonary fibrosis.In 4 separate research cohorts, interstitial lung abnormalities were associated with a greater risk of all-cause mortality. The clinical implications of this association require further investigation.National Institutes of Health (NIH)
T32 HL007633
Icelandic Research Fund
141513-051
Landspitali Scientific Fund
A-2015-030
National Cancer Institute grant
1K23CA157631
NIH
K08 HL097029
R01 HL113264
R21 HL119902
K25 HL104085
R01 HL116931
R01 HL116473
K01 HL118714
R01 HL089897
R01 HL089856
N01-AG-1-2100
HHSN27120120022C
P01 HL105339
P01 HL114501
R01 HL107246
R01 HL122464
R01 HL111024
National Heart, Lung, and Blood Institute's Framingham Heart Study contract
N01-HC-2519.5
GlaxoSmithKline
NCT00292552
5C0104960
National Institute on Aging (NIA) grant
27120120022C
NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association)
Althingi (the Icelandic Parliament)
NIA
27120120022
- …